

DOI: 10.4274/jcrpe.galenos.2025.2024-9-13

Review

Noonan Syndrome, Cancer Risk, and Growth Hormone Treatment

Demir K and Yüksek Acımlı K. Noonan Syndrome, Cancer Risk, and Growth Hormone Treatment

Korcan Demir, Kübra Yüksek Acımlı
Pediatric Endocrinology, Dokuz Eylül University, Faculty of Medicine, İzmir, Türkiye

Abstract

Cancer can occur in patients with Noonan syndrome (NS). Review of English literature revealed that myeloproliferative diseases are the most prevalent, followed by intracranial tumours. There is no genotype phenotype relationship between germline pathogenic variants so it not possible to precisely predict cancer risk in NS, however some *PTPN11* variants are exclusively detected in juvenile myelomonocytic leukemia and are not observed in other types of cancer. Among patients on growth hormone, cancer development was reported in seven patients with genetically confirmed NS, and five patients with clinically diagnosed NS. However, information on growth hormone dose, timing, and follow-up characteristics in these cases is heterogeneous. In the light of current data, especially in cases for whom growth hormone therapy is considered, the diagnosis should be genetically confirmed, and the results of genetic analysis should be compared with the cases reported in the literature. Families should be informed about possible cancer risk and in cases predisposing to juvenile myelomonocytic leukemia, early initiation of growth hormone therapy should be avoided.

Keywords: Rasopathy; growth retardation; somatotropin, oncogenesis, malignancy

Korcan Demir MD, Prof., Pediatric Endocrinology, Dokuz Eylül University, Faculty of Medicine, İzmir, Turkey
korcan.demir@deu.edu.tr, korcandemir@gmail.com
0000-0002-8334-2422
23.09.2024
09.02.2025

Epub: 20.02.2025

1. Introduction

Noonan syndrome (NS) is the most common type of RASopathies. Related main overlapping disorders are Noonan syndrome and multiple lentiginos (NS-ML), cardiofasciocutaneous syndrome (CFCS), Costello syndrome (CS), neurofibromatosis type 1 (NF1), Legius syndrome (LS), and Noonan syndrome-like disorder with loose anagen hair (1)(2)(3). In this review, we focused on Noonan syndrome in order to ensure the accuracy of diagnosis and strengthen the reliability of the findings by minimizing potential misclassification of overlapping conditions. Somatic mutations in the genes of the RAS/MAPK pathway (i.e., *PTPN11*, *KRAS*, *HRAS*, *NRAS*, *NFI*, and *CBL*), which are involved in regulating cell growth, division, and differentiation in response to growth factors, have been shown to play a crucial role in cancer development. For instance, *PTPN11* encodes SHP-2, a tyrosine phosphatase enzyme that modulates intracellular signaling and mutations in *PTPN11* lead to abnormal activity of this enzyme and disrupt normal signaling processes. Furthermore, somatic mutations in *PTPN11* enhancing phosphatase activity of mutant SHP-2 were detected in childhood leukemia (4). Mutations in *KRAS* and *NRAS* may lead to hyperactive RAS/MAPK pathway due to defective intrinsic GTPase activity (5). As a result, there have been concerns regarding the potential genetic predisposition to cancer in individuals with Noonan syndrome (NS), which occurs with germline and mostly heterozygous changes of some genes in this pathway. The use of growth hormone (GH) therapy for short stature in NS further increases the concerns (6)(7). On the other hand, GH therapy was approved by the US Food and Drug Administration (FDA) in 2007 for NS cases with short stature, and there is still no global consensus on routine cancer screening in NS (8)(9)(10).

Considering that NS had an average prevalence of 1 in 2000 in the overall population, the number of reported cancer cases is relatively low. On one hand, this might be explained by the fact that certain cases of NS exhibit subtle symptoms, possibly resulting in the underdiagnosis. On the other hand, NS-related variants might not be directly associated with cancer and various additional genetic changes may have indeed contributed to the development of oncogenic processes in NS cases. Studies have recently shown the presence of hyperdiploid karyotype in the leukemic cells of a significant portion of ALL cases (36-73%) carrying a germline *PTPN11* variant. It has been proposed that additional factors such as chromosome breaks or certain epigenetic influences may contribute to an increased susceptibility to cancer in patients with NS (11)(12). Some studies observed a relationship between uniparental disomy in several genes and oncogenesis (16) (13). Interestingly, in a NS patient with ALL, the germline *PTPN11* variant was not present in the leukemic cells, suggesting other mechanisms (14).

2. Method

A literature review was conducted using web search tools including PubMed, OMIM, and Google Scholar (1987 to present; last access date September 23rd, 2024) using the search terms "Noonan" or "Noonan Syndrome" to identify all relevant case reports or cohorts. The reference list of all articles was also searched to identify further relevant publications. We included only patients clinically and genetically diagnosed with NS. All cases with NS-like syndromes, such as NF-1 with NS features, were excluded. We should point out that clinical and genetic data in the published reports were heterogeneous; most articles presented insufficient clinical details about the cases, and there was a notable absence of comprehensive analyses of other conditions that might contribute to cancer predisposition. It was considered that the cases did not receive GH treatment if it was not mentioned.

3. Cancer in Noonan syndrome patients who did not receive growth hormone

There are various data regarding the general cancer frequency in NS. The first comprehensive report on this topic reviewing the literature from 1937 to 2010 found 46 cancer events in 45 cases (3.9%) among 1151 subjects with either clinical or genetic diagnosis of NS. It has been stated that the age at cancer diagnosis was similar to that seen in the general population (15). In this cohort, 73% of the cases were 20 years of age or younger, with the predominant cancers being neuroblastoma (8 patients), acute lymphoblastic leukemia (ALL) (8 patients), glioma (6 patients), and rhabdomyosarcoma (6 patients). This article, which has been frequently cited in reviews, has important limitations, such as a lack of genetic investigation in many cases and the exclusion of myeloproliferative disorders.

Table 1 presents the list of histopathologically confirmed malignant tumors reported in the literature among pediatric cases with NS, whose diagnoses were confirmed through genetic analysis. For the small number of cases with multiple cancers, we recorded the first one. Myeloproliferative diseases are the most common, followed by intracranial tumors among solid tumors. The cancers were generally linked to variants in *PTPN11*, a prevalent cause of NS. The T73I variant in *PTPN11* has only been found in cases with juvenile myelomonocytic leukemia (JMML), the other variants were present in various tumor types. Since many of the variants listed are also found in NS cases who did not develop cancer, no clear correlation can be established between the *PTPN11* variants and the occurrence of cancer (16)(17)(4)(18)(19)(20)(21)(22)(14)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(11)(39)(40)(41)(12)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54) (55)(56)(57)(58)(59)(60) (61).

Myeloproliferative diseases in NS can present in two different clinical situations. While most of the cases have a benign course, the remaining cases progress aggressively; this type is called JMML and it is rarely seen in children without NS. The association between this form of leukemia and Noonan syndrome was initially reported by Tartaglia et al. in 2003 (16). Nevertheless, comprehensive details regarding the clinical characteristics of the patients were not provided at that time. In a study covering a 10-year period from a reference hospital from France, JMML was found to be present in 20 (3.12%) of 641 NS cases with a *PTPN11* variant (Table 1). JMML-related findings had appeared in the first three months of life in all cases, and interestingly, a history of polyhydramnios may be a warning sign for development of JMML since its incidence was significantly higher in such cases (50%) compared to the NS cases who did not develop JMML (11.7%) (31). Additionally, majority of the *PTPN11* variants detected in NS cases with JMML were also found in NS patients without myeloproliferative diseases (38). A study published later from same center reported that acute lymphoblastic leukemia (ALL) occurred in 4 out of 778 cases (0.5%) with a *PTPN11* variant and in 2 out of 94 cases (2.1%) with a variant in the *SOS1* gene (Table 1) (12).

In a study including data of NS patients collected from 25 molecular genetic laboratories in Germany, 8 out of 632 (1.27%) children had cancer. Importantly, all these cases had a *PTPN11* variant (Table 1). Based on these findings, the risk of developing childhood cancer in NS was estimated to be 8.1-fold increased; however, the risk of developing acute lymphoblastic leukemia (ALL) and neuroblastoma appeared to be similar with that of the general population. In the same study, the risk of developing cancer in those with Costello syndrome and those with a *KRAS* variant was 42.4-fold and 75.8-fold increased, respectively (40).

In a study from the Netherlands, among 297 subjects with NS with a *PTPN11* variant, 12 (4.04%, 4 children, 8 adults) patients developed cancer during a median follow-up duration of 13 years. It was concluded that the risk of developing cancer until the age of 55 was 3.5 times higher compared to the general population (Table 1) (62).

In a study from Italy, among the 35 NS cases with a clinical and/or genetic diagnosis, 2 (5.7%) patients with a *PTPN11* variant had developed a cancer. Unfortunately, specific variants were not mentioned (63).

A study from China reviewed 102 patients with NS, five of whom carried *PTPN11* variants and were found to have tumors. Among these, two were diagnosed with JMML, two with neuroblastoma, and one with ALL (58).

Among the 107 Noonan syndrome (NS) patients with *RAF* mutations reported in the Italian cohort, 20 were newly identified cases. Two cancer cases were noted, but the specific types of cancer were not provided (60). Genetic findings of subjects with Noonan syndrome and cancer reported in case reports have been given in Table 1, however, we could not include a 14-year-old boy with T-cell ALL and glioblastoma since the variant in *PTPN11* was not specified (80).

There are also a few case reports of rhabdomyosarcoma in patients with a clinical diagnosis of NS (64)(65). On the contrary, no cancer was reported among some studies from various countries covering over 1000 cases (66)(67)(68)(69) (70) (71) (72) (73) (74) (75) (76) (77).

4. Cancer in Noonan syndrome patients treated with growth hormone

The relationship between GH therapy and cancer has been an ongoing debate for several years since elevated levels of insulin-like growth factor 1 (IGF1) have been identified as a potential risk factor for the development of certain tumours and congenital IGF1 deficiency appears to provide a protective effect against cancer (78). Based on data obtained from case series, the treatment of GH for idiopathic GH deficiency, idiopathic short stature, and short stature in infants born small for gestational age is generally not associated with an increased risk of cancer. Notably, cases with a history of cancer, those with predisposing conditions like neurofibromatosis, Down syndrome, chromosomal breakage, or DNA repair abnormalities have a natural vulnerability to developing cancer (79). Regarding Noonan syndrome, while various animal models with RASopathies exist, the effects of the relevant gene mutations in response to growth hormone therapy have not been studied in these models (1). The outcomes of GH treatment in humans with Noonan syndrome have been reported in the medical literature since it was first used in 1987 (80). We categorized the reported cancer cases into two subheadings based on the type of diagnosis (clinical diagnosis only vs clinical and/or genetic diagnosis) given that neurofibromatosis type 1, which is well known to have a predisposition to cancer, was reported to be the underlying condition in some cases with a clinical diagnosis of NS without even café-au-lait spots (81). Furthermore, eight cases reported in congresses were not included (42). However, the data exhibited heterogeneity in dose and timing of GH treatment, IGF1 levels, duration of follow-up, and genetic analysis information. We have summarized the relevant data as much as possible.

a. Cases with a clinical diagnosis of NS

In a single center study from Sweden, the outcomes of GH treatment in 25 children with NS were reported. Ten of the cases were initially treated with a dose of 0.23 mg/kg/week, while the remaining 15 were treated with a dose of 0.46 mg/kg/week. According to the study protocol, dose adjustments were made two years later, and after three years of GH treatment, one patient out of 25 (4%) developed lymphoma (82).

Data from the US registry of a GH manufacturer company revealed that a possible left parietal lobe tumor developed in one of 65 cases (1.5%). The reported average dose of the GH was 0.33 mg/kg/week, and the case achieved adult height (83).

An atypical granular cell tumor, of which the histological features could not definitively distinguish between benign or malignant, was reported in a 10-year-old girl. This case was treated with GH for three years; after surgical excision, no recurrence developed during follow-up (84).

In a study performed on cases who received GH for a duration exceeding four years using an international registry of another GH manufacturer company, two cases, aged 9.5 and 10 years, developed glioneuronal tumor and a brain tumor (for which no clear information is available) after GH therapy for 1.2 and 2.5 years, respectively (7).

b. NS cases with genetic data

In an international study published in 2010, *SOS1* analysis was performed in 102 cases without *PTPN11* or *KRAS* mutations. The study reported that a 4-year-old patient with the P102R variant in the *SOS1* gene developed rhabdomyosarcoma, while another 4-year-old patient with the M269T variant was diagnosed with a Sertoli cell tumor. Although growth hormone therapy was noted in both cases, no further details regarding the timing, dosage, or follow-up of the treatment were provided (85).

In 2016, it was reported that an 8-year-old patient with NS who had been receiving growth hormone therapy for the past 4 years and had an E139D variant in *PTPN11* was diagnosed with a dysembryoplastic neuroepithelial tumor. Upon reviewing the cranial MRI images taken for another reason when the patient was 1.5 years old, smaller lesions, previously described as nonspecific, were identified in the same regions where the current lesions were found. However, no detailed information regarding endocrine follow-up was provided (42).

In 2017, an 8-year-old patient with a D61G variant in *PTPN11* was reported to develop a low-grade dysembryoplastic neuroepithelial tumor in the 15th month of growth hormone therapy. The dose was 0.3 mg/kg/week and IGF-1 level 115 ng/mL during the first six months of treatment. A subtotal resection was performed, and the growth hormone treatment was stopped. At the end of the first year, due to a low growth rate, growth hormone therapy was restarted without a stimulation test. The IGF-1 level was maintained between 1 and 2 SDS according to the patient's age and pubertal stage, and MRI follow-up showed no growth in the residual mass. In a second patient reported by the same center, with an N308D variant in *PTPN11*, no pathology was found in a cranial MRI taken for migraines at the age of 9.5. At 13.5 years of age, growth hormone therapy was started without a stimulation test at a dose of 0.35 mg/kg/week. During follow-up, maximum dose was 0.4 mg/kg/week and IGF-1 levels were in the normal range. In the 18th month of treatment, the patient presented to the emergency department with confusion and was diagnosed with pilocytic astrocytoma, leading to the discontinuation of growth hormone therapy (45).

Recently, *LZTR1* mutations have been found to cause NS through either autosomal dominant or recessive inheritance. In 2020, it was reported that a patient with a heterozygous R284C variant in this gene, who had been using growth hormone at a dose of 0.23-0.25 mg/kg/week between the ages of 15 and 17, developed an oligoastrocytoma at the age of 22 (50).

In a study evaluating cases from an international database of a growth hormone manufacturing company, including patients who had received treatment for more than 4 years, an adolescent with an unspecified *PTPN11* mutation was reported to have developed a pilocytic astrocytoma and spinal metastases after 2.5 years of growth hormone treatment (78). A few years later, the same company reported another case, who was a 9-year-old male with an unspecified *PTPN11* variant and a brain neoplasm (dysembryoplastic neuroepithelial tumor) 14 months after initiation of GH treatment (81).

In another case report, the nine-year-old patient, who had been diagnosed with Noonan syndrome in infancy and carried a R501K variant in *PTPN11*, was diagnosed with medium-risk T-ALL after receiving growth hormone (GH) treatment for a 3-year period. Unfortunately, no more information on GH treatment was given (54).

5. Conclusion

The article published by the Pediatric Endocrine Society (PES) in 2015 in the United States discussed the cancer risk in patients treated with GH, and NS was assessed as one of the conditions that predispose individuals to tumor development in these patients (79). On the other hand, a report in 2017 published by a group primarily consisting of oncology specialists from the USA, Germany, Japan, and Canada emphasized the significance of performing physical examinations, blood counts, and blood smear tests during the initial 5 years of life for cases with a genetic variant that may be associated with juvenile myelomonocytic leukaemia (JMML). This report recommended using a blood smear as a screening method for this group. However, it was not recommended for cases with genetic variants that were not linked to developing JMML, as there was a minimal risk of developing cancer in this group. Therefore, routine screening was considered unnecessary, and it was emphasized that cases should be warned for further evaluation if they experience any symptoms that may be a sign of a tumor (86).

As a general approach by Pediatric Endocrine Society (PES) in US, if growth hormone treatment is started in cases with a predisposition to cancer, such as a genetic disease, although there is no evidence to support or contradict it, the cautious approach is to keep blood IGF1 levels at age-appropriate levels and to perform routine cancer screening according to disease specific guidelines, however there are no generally accepted cancer screening guidelines for NS (83).

Based on the current literature and recommendations, particularly in cases of NS when GH treatment is being considered, it is advisable to (i) confirm the diagnosis through genetic analysis, (ii) compare the identified genetic changes with cases documented in the literature, (iii) avoid the early initiation of GH treatment in individuals who are at risk for Juvenile Myelomonocytic Leukemia (JMML), and (iv) appropriately communicate potential risks with families and establish a comprehensive follow-up plan.

References

1. Tajan M, Paccoud R, Branka S, Edouard T, Yart A. The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway. *Endocrine reviews* [Internet]. 2018 Oct 1 [cited 2024 Dec 5];39(5):676–700. Available from: <https://pubmed.ncbi.nlm.nih.gov/29924299/>
2. Zenker M. Clinical overview on RASopathies. *American journal of medical genetics Part C, Seminars in medical genetics* [Internet]. 2022 Dec 1 [cited 2024 Dec 11];190(4):414–24. Available from: <https://pubmed.ncbi.nlm.nih.gov/36428239/>
3. Tartaglia M, Aoki Y, Gelb BD. The molecular genetics of RASopathies: An update on novel disease genes and new disorders. *American journal of medical genetics Part C, Seminars in medical genetics* [Internet]. 2022 Dec 1 [cited 2024 Dec 24];190(4):425–39. Available from: <https://pubmed.ncbi.nlm.nih.gov/36394128/>
4. Niihori T, Aoki Y, Ohashi H, Kurosawa K, Kondoh T, Ishikiriya S, et al. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. *Journal of Human Genetics*. 2005;50(4):192–202.
5. Cuevas-Navarro A, Pourfarjam Y, Hu F, Rodriguez DJ, Vides A, Sang B, et al. Pharmacological restoration of GTP hydrolysis by mutant RAS. *Nature* [Internet]. 2025 [cited 2024 Dec 24];637(8044). Available from: <https://pubmed.ncbi.nlm.nih.gov/39476862/>
6. AE R, Roberts AE. 2022. Noonan syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. *GeneReviews* [Internet]. Seattle, WA: University of Washington, Seattle.
7. Rohrer TR, Abuzahab J, Backeljauw P, Birkegård AC, Blair J, Dahlgren J, et al. Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome. *Hormone Research in Paediatrics*. 2021;93(6):380–95.
8. García-Miñaur S, Burkitt-Wright E, Verloes A, Shaikh G, Lebl J, Östman-Smith I, et al. European Medical Education Initiative on Noonan syndrome: A clinical practice survey assessing the diagnosis and clinical management of individuals with Noonan syndrome across Europe. *European journal of medical genetics* [Internet]. 2022 Jan 1 [cited 2024 Jan 8];65(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/34757053/>
9. Noonan JA, Kappelgaard AM. The efficacy and safety of growth hormone therapy in children with noonan syndrome: A review of the evidence. *Hormone Research in Paediatrics*. 2015;83(3):157–66.
10. Burkitt-Wright EMM, Kerr B. Noonan syndrome. In: UpToDate, Tepas E (Ed), UpToDate, Waltham, MA (last update 08.01.2024).
11. Sakamoto K, Imamura T, Asai D, Goto-Kawashima S, Yoshida H, Fujiki A, et al. Acute lymphoblastic leukemia developing in a patient with noonan syndrome harboring a PTPN11 germline mutation. *Journal of Pediatric Hematology/Oncology* [Internet]. 2014 Mar [cited 2024 Jan 16];36(2):e136–9. Available from: <https://tohoku.elsevierpure.com/en/publications/acute-lymphoblastic-leukemia-developing-in-a-patient-with-noonan->
12. Cavé H, Caye A, Strullu M, Aladjidi N, Vignal C, Ferster A, et al. Acute lymphoblastic leukemia in the context of RASopathies. *European Journal of Medical Genetics*. 2016;59(3):173–8.
13. Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debemardi S, Skoulakis S, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. *Cancer Research*. 2005;65(20):9152–4.

14. Karow A, Steinemann D, Göhring G, Hasle H, Greiner J, Harila-Saari A, et al. Clonal duplication of a germline PTPN11 mutation due to acquired uniparental disomy in acute lymphoblastic leukemia blasts from a patient with Noonan syndrome [2]. *Leukemia*. 2007;21(6):1303–5.
15. Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*. 2011;157(2):83–9.
16. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. *Nature Genetics*. 2003;34(2):148–50.
17. Jongmans M, Otten B, Noordam K, van der Burgt I. Genetics and variation in phenotype in Noonan syndrome. *Hormone research*. 2004;62 Suppl 3(suppl 3):56–9.
18. Merks JHM, Caron HN, Hennekam RCM. High incidence of malformation syndromes in a series of 1,073 children with cancer. *American Journal of Medical Genetics*. 2005;134 A(2):132–43.
19. Jongmans M, Sijm EA, Rikken A, Nillesen WM, Tamminga R, Patton M, et al. Genotypic and phenotypic characterization of Noonan syndrome: New data and review of the literature. *American Journal of Medical Genetics*. 2005;134 A(2):165–70.
20. Schubert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, et al. Germline KRAS mutations cause Noonan syndrome. *Nature Genetics*. 2006;38(3):331–6.
21. Giovanni Rotil Roberta La Starza1 Stelvio Ballanti1 Barbara Crescenzi1 Silvia Romoli1 Robin Foa`2 Marco Tartaglia3 Franco Aversa1 Massimo Fabrizio Martelli1 Cristina Mecucci. Acute lymphoblastic leukaemia in Noonan syndrome. *British Journal of Haematology*. 2006;133(4):446–8.
22. Martinelli S, Carta C, Flex E, Binni F, Cordisco EL, Moretti S, et al. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. *Cancer genetics and cytogenetics [Internet]*. 2006 Apr 15 [cited 2024 Feb 29];166(2):124–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/16631468/>
23. Chantrain CF, Jijon P, De Raedt T, Vermeylen C, Poirel HA, Legius E, et al. Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation. *Pediatric blood & cancer [Internet]*. 2007 Jan [cited 2024 Mar 1];48(1):101–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/16078230/>
24. Moschovi M, Vassiliki T, Anna P, Maria-Alexandra M, Polyxeni NK, Sophia KT. Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature. *Journal of pediatric hematology/oncology [Internet]*. 2007 May [cited 2024 Dec 24];29(5):341–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/17483716/>
25. Yoshida R, Miyata M, Nagai T, Yamazaki T, Ogata T. A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia. *American journal of medical genetics Part A [Internet]*. 2004 Jul [cited 2024 Dec 24];128A(1):63–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/15211660/>
26. Mutesa L, Pierquin G, Janin N, Segers K, Thomée C, Provenzi M, et al. Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors. *Cancer Genetics and Cytogenetics*. 2008;182(1):40–2.
27. Yoshida R, Ogata T, Masawa N, Nagai T. Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation. *Pediatric blood & cancer [Internet]*. 2008 Jun [cited 2024 Jan 16];50(6):1274–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/18253957/>
28. De Filippi P, Zecca M, Lisini D, Rosti V, Cagioni C, Carlo-Stella C, et al. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. *British Journal of Haematology*. 2009;147(5):706–9.
29. Sherman CB, Ali-Nazir A, Gonzales-Gomez I, Finlay JL, Dhall G. Primary mixed glioneuronal tumor of the central nervous system in a patient with Noonan syndrome: a case report and review of the literature. *Journal of pediatric hematology/oncology [Internet]*. 2009 Jan [cited 2024 Mar 1];31(1):61–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/19125092/>
30. Schuettelpelz LG, McDonald S, Whitesell K, Desruisseau DM, Grange DK, Gurnett CA WD. Pilocytic astrocytoma in a child with Noonan syndrome. *Pediatr Blood Cancer. Pediatric Blood & Cancer*. 2009;
31. Jongmans MCJ. Noonan Syndrome, the SOS1 Gene and Embryonal Rhabdomyosarcoma. *Cancer*. 2011;396(January):389–96.
32. Rob Hastings and Ruth Newbury-Ecob. A Further Patient with Noonan Syndrome Due to a SOS1 Mutation and Rhabdomyosarcoma. *Cancer*. 2011;396(January):389–96.
33. Denayer E, Devriendt K, De Ravel T, Van Buggenhout G, Smeets E, Francois I, et al. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations. *Genes, Chromosomes and Cancer [Internet]*. 2010 Mar 1 [cited 2024 Jan 16];49(3):242–52. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/gcc.20735>
34. Jongmans MCJ, Van Der Burgt I, Hoogerbrugge PM, Noordam K, Yntema HG, Nillesen WM, et al. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. *European Journal of Human Genetics [Internet]*. 2011;19(8):870–4. Available from: <http://dx.doi.org/10.1038/ejhg.2011.37>
35. Pauli S, Steinemann D, Dittmann K, Wienands J, Shoukier M, Möschner M, et al. Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D. *American Journal of Medical Genetics, Part A*. 2012;158 A(3):652–8.
36. Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. *American Journal of Human Genetics [Internet]*. 2013;93(1):173–80. Available from: <http://dx.doi.org/10.1016/j.ajhg.2013.05.021>
37. Rankin J, Short J, Turnpenny P, Castle B, Hanemann CO. Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation. *American Journal of Medical Genetics, Part A*. 2013;161(8):2027–9.
38. Strullu M, Caye A, Lachenaud J, Cassinat B, Gazal S, Fenneteau O, et al. Juvenile myelomonocytic leukaemia and Noonan syndrome. *Journal of Medical Genetics*. 2014;51(10):689–97.
39. Bertola DR, Yamamoto GL, Almeida TF, Buscarilli M, Jorge AAL, Malaquias AC, et al. Further evidence of the importance of RIT1 in Noonan syndrome. *American Journal of Medical Genetics Part A [Internet]*. 2014 Nov 1 [cited 2024 Mar 4];164(11):2952–7. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.a.36722>
40. Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, et al. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. *British Journal of Cancer*. 2015;112(8):1392–7.
41. Nair S, Fort JA, Yachnis AT, Williams CA. Optic nerve pilomyxoid astrocytoma in a patient with Noonan syndrome. *Pediatric blood & cancer [Internet]*. 2015 Jun 1 [cited 2024 Jan 16];62(6):1084–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/25585602/>
42. McWilliams GD, Santacruz K, Hart B, Clericuzio C. Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy. *American Journal of Medical Genetics, Part A*. 2016;170(1):195–201.
43. Mason-Suares H, Toledo D, Gekas J, Lafferty KA, Meeks N, Pacheco MC, et al. Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome. *European Journal of Human Genetics [Internet]*. 2017;25(4):509–11. Available

from: <http://dx.doi.org/10.1038/ejhg.2016.202>

44. Siegfried A, Cances C, Denuelle M, Loukh N, Tauber M, Cavé H, et al. Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature. *American Journal of Medical Genetics, Part A*. 2017;173(4):1061–5.
45. Bangalore Krishna K, Pagan P, Escobar O, Popovic J. Occurrence of Cranial Neoplasms in Pediatric Patients with Noonan Syndrome Receiving Growth Hormone: Is Screening with Brain MRI prior to Initiation of Growth Hormone Indicated? *Hormone Research in Paediatrics*. 2017;88(6):423–6.
46. Johnston JJ, van der Smagt JJ, Rosenfeld JA, Pagnamenta AT, Alswaid A, Baker EH, et al. Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants. *Genetics in Medicine*. 2018;20(10):1175–85.
47. Eriksen B, Savage N, Stansfield B, Mann P. A novel mutation in PTPN11 in an extremely preterm infant with suspected juvenile myelomonocytic leukemia. *Journal of Clinical Neonatology* [Internet]. 2018 [cited 2024 Jan 16];7(4):269. Available from: https://journals.lww.com/jocn/fulltext/2018/07040/a_novel_mutation_in_ptpn11_in_an_extremely_preterm.15.aspx
48. El-Ayadi M, Ansari M, Kühnöl CD, Bendel A, Sturm D, Pietsch T, et al. Occurrence of high-grade glioma in Noonan syndrome. Report of two cases. *Pediatric Blood and Cancer*. 2019;66(5):9–12.
49. Lodi M, Boccuto L, Carai A, Cacchione A, Miele E, Colafati GS, et al. Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature. *Diagnostics*. 2020;10(8):1–11.
50. Jacquinet A, Bonnard A, Capri Y, Martin D, Sadzot B, Bianchi E, et al. Oligo-astrocytoma in LZTR1-related Noonan syndrome. *European Journal of Medical Genetics* [Internet]. 2020;63(1):103617. Available from: <https://doi.org/10.1016/j.ejmg.2019.01.007>
51. Nagatomo K, Fukushima H, Kanai Y, Muramatsu H, Takada H. A neonate diagnosed with Noonan syndrome with myeloproliferative change. *Pediatrics international : official journal of the Japan Pediatric Society* [Internet]. 2021 Dec 1 [cited 2024 Jan 17];63(12):1521–3. Available from: <https://pubmed.ncbi.nlm.nih.gov/34355465/>
52. Weinstock NI, Sadler L. The RAS2 pathogenic variant p . Q72L produces severe Noonan syndrome with hydrocephalus : A case report. 2022;1(February 2021):364–8.
53. Harms FL, Alawi | Malik, David |, Amor J, Tiong |, Tan Y, et al. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor. 2017 [cited 2024 Sep 13]; Available from: <https://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.38569>
54. Kaya Z, Keser E, Atalay E, Kayhan G, Karamercan S, Topuz B, et al. Two distinct syndromic children with T-acute lymphoblastic leukemia: Noonan syndrome and Sotos syndrome. *Leukemia research* [Internet]. 2022 Dec 1 [cited 2024 Sep 11];123. Available from: <https://pubmed.ncbi.nlm.nih.gov/36356491/>
55. Garren B, Stephan M, Hogue JS. NRAS associated RASopathy and embryonal rhabdomyosarcoma. *American Journal of Medical Genetics, Part A*. 2020 Jan 1;182(1):195–200.
56. Suzuki K, Wakamatsu M, Ito Y, Ishikawa M, Shimotakahara A, Futagawa H, et al. Myeloproliferative disorder in a patient with RIT1-associated Noonan syndrome: Case report and literature review. *Pediatric blood & cancer* [Internet]. 2024 Feb 1 [cited 2024 Jan 17];71(2). Available from: <https://pubmed.ncbi.nlm.nih.gov/38015090/>
57. Wu X, Wu J, Yuan Y, Yang L, Yu L. Noonan syndrome: rhGH treatment and PTPN11 mutation. *Molecular genetics & genomic medicine* [Internet]. 2023 Nov 1 [cited 2024 Jan 16];11(11). Available from: <https://pubmed.ncbi.nlm.nih.gov/37525886/>
58. Li X, Yao R, Tan X, Li N, Ding Y, Li J, et al. Molecular and phenotypic spectrum of Noonan syndrome in Chinese patients. *Clinical genetics* [Internet]. 2019 Oct 1 [cited 2024 Sep 10];96(4):290–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/31219622/>
59. Dentici ML, Niceta M, Lepri FR, Mancini C, Priolo M, Bonnard AA, et al. Loss-of-function variants in ERF are associated with a Noonan syndrome-like phenotype with or without craniostenosis. [cited 2024 Sep 10]; Available from: <https://doi.org/10.1038/s41431-024-01642-7>
60. Gazzin A, Fomari F, Niceta M, Leoni C, Lisa Dentici M, Carli D, et al. Defining the variant-phenotype correlation in patients affected by Noonan syndrome with the RAF1:c.770C>T p.(Ser257Leu) variant. [cited 2024 Sep 10]; Available from: <https://doi.org/10.1038/s41431-024-01643-6>
61. Yang F, Long N, Anekpuranang T, Bottomly D, Savage JC, Lee T, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. *Blood* [Internet]. 2022 Feb 24 [cited 2024 Sep 11];139(8):1208–21. Available from: <https://dx.doi.org/10.1182/blood.2021011354>
62. Jongmans MCJ, Van Der Burgt I, Hoogerbrugge PM, Noordam K, Yntema HG, Nillesen WM, et al. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. *European Journal of Human Genetics* [Internet]. 2011;19(8):870–4. Available from: <http://dx.doi.org/10.1038/ejhg.2011.37>
63. Baldo F, Fachin A, Da Re B, Rubinato E, Bobbo M, Barbi E. New insights on Noonan syndrome’s clinical phenotype: a single center retrospective study. *BMC pediatrics* [Internet]. 2022 Dec 1 [cited 2024 Sep 10];22(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/36566191/>
64. Khan S, McDowell H, Upadhyaya M, Fryer A. Vaginal rhabdomyosarcoma in a patient with Noonan syndrome. *Journal of Medical Genetics*. 1995;32(9):743–5.
65. Jung A, Bechtold S, Pfluger T, Renner C, Ehrh O. Orbital rhabdomyosarcoma in Noonan syndrome. *Journal of Pediatric Hematology/Oncology*. 2003;25(4):330–2.
66. Şıklar Z, Genens M, Poyrazoğlu Ş, Baş F, Darendeliler F, Bundak R, et al. The growth characteristics of patients with Noonan syndrome: Results of three years of growth hormone treatment: A nationwide multicenter study. *JCRPE Journal of Clinical Research in Pediatric Endocrinology*. 2016;8(3):305–12.
67. Jeong I, Kang E, Cho JH, Kim G-H, Lee BH, Choi J-H, et al. Long-term efficacy of recombinant human growth hormone therapy in short-statured patients with Noonan syndrome. *Annals of Pediatric Endocrinology & Metabolism*. 2016;21(1):26.
68. Ranke MB, Lindberg A, Carlsson M, Camacho-Hübner C, Rooman R. Treatment with growth hormone in noonan syndrome observed during 25 years of KIGS: Near adult height and outcome prediction. *Hormone Research in Paediatrics*. 2019;91(1):46–55.
69. Athota JP, Bhat M, Nampoothiri S, Gowrishankar K, Narayanachar SG, Puttamalles V, et al. Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations. *BMC Medical Genetics*. 2020;21(1):1–10.
70. Papadopoulou G, Papadopoulou A, Kosma K, Papadimitriou A, Papaevangelou V, Kanaka-Gantenbein C, et al. Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients. *European journal of pediatrics* [Internet]. 2022 Oct 1 [cited 2024 Sep 11];181(10):3691–700. Available from: <https://pubmed.ncbi.nlm.nih.gov/35904599/>
71. De Schepper J, Thomas M, Huysentruyt K, Becker M, Boros E, Casteels K, et al. Near adult height and BMI changes in growth hormone treated short children with Noonan syndrome: the Belgian experience. *Hormone research in paediatrics* [Internet]. 2024 [cited 2024 Sep

11]; Available from: <https://pubmed.ncbi.nlm.nih.gov/38432193/>

72. Chen Q, Hong D, Huang Y, Zhang Z, Wang S. Phenotypic and genotypic spectrum of noonan syndrome: A retrospective analysis of 46 consecutive pediatric patients presented at a regional cardiac center in China. *Heliyon* [Internet]. 2024 Mar 15 [cited 2024 Sep 11];10(5). Available from: <https://pubmed.ncbi.nlm.nih.gov/38463782/>

73. Rabelo NC, Gomes ME, Moraes I de O, Pfisterer JC, de Moraes GL, Antunes D, et al. RASopathy Cohort of Patients Enrolled in a Brazilian Reference Center for Rare Diseases: A Novel Familial LZTR1 Variant and Recurrent Mutations. The application of clinical genetics [Internet]. 2022 [cited 2024 Sep 11];15:153–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/36304179/>

74. Uludağ Alkaya D, Lissewski C, Yeşil G, Zenker M, Tüysüz B. Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1. *American journal of medical genetics Part A* [Internet]. 2021 Dec 1 [cited 2024 Sep 11];185(12):3623–33. Available from: <https://pubmed.ncbi.nlm.nih.gov/34184824/>

75. Shoji Y, Hata A, Maeyama T, Wada T, Hasegawa Y, Nishi E, et al. Genetic backgrounds and genotype-phenotype relationships in anthropometric parameters of 116 Japanese individuals with Noonan syndrome. *Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology* [Internet]. 2024 [cited 2024 Sep 11];33(2):50–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/38572385/>

76. Wu X, Wu J, Yuan Y, Yang L, Yu L. Noonan syndrome: rhGH treatment and PTPN11 mutation. *Molecular genetics & genomic medicine* [Internet]. 2023 Nov 1 [cited 2024 Sep 11];11(11). Available from: <https://pubmed.ncbi.nlm.nih.gov/37525886/>

77. Cappa M, d'Aniello F, Digilio MC, Gagliardi MG, Minotti C, Leoncini PP, et al. Noonan Syndrome Growth Charts and Genotypes: 15-Year Longitudinal Single-Centre Study. *Hormone research in paediatrics* [Internet]. 2024 Jul 22 [cited 2024 Sep 13];1–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/38964306/>

78. Cianfarani S. Safety of Pediatric rhGH Therapy: An Overview and the Need for Long-Term Surveillance. *Frontiers in Endocrinology*. 2021;12(December):1–6.

79. Raman S, Grimberg A, Waguespack SG, Miller BS, Sklar CA, Meacham LR, et al. Risk of neoplasia in pediatric patients receiving growth hormone therapy - A report from the pediatric endocrine society drug and therapeutics committee. *Journal of Clinical Endocrinology and Metabolism*. 2015;100(6):2192–203.

80. Cianfarani S, Spadoni GL, Finocchi G, Ravet P, Costa F, Papa M, Scirè G, Manca Bitti ML BBT con ormone della crescita (GH) in tre casi di sindrome di N [Treatment with growth hormone (GH) in 3 cases of N syndrome]. *MP* 1987 A 15;39(7):281-4. IP 3614154. No Title. *Minerva Pediatr*. 1987;

81. Witkowski L, Dillon MW, Murphy E, S Lebo M, Mason-Suares H. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1. *Molecular Genetics and Genomic Medicine*. 2020;8(4).

82. Dahlgren, JovannOslo D, Wikland KA, Westphal O. Improved final height with long-term growth hormone treatment in Noonan syndrome. *Acta Paediatrica, International Journal of Paediatrics*. 2005;94(9):1232–7.

83. Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, Jacobs J, et al. Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone. *Journal of Clinical Endocrinology and Metabolism*. 2009;94(7):2338–44.

84. Moos D, Droitcourt C, Rancherevince D, Marec Berard P, Skowron F. Atypical granular cell tumor occurring in an individual with Noonan syndrome treated with growth hormone. *Pediatric Dermatology*. 2012;29(3):665–6.

85. Denayer E, Devriendt K, de Ravel T, Van Buggenhout G, Smeets E, Francois I, Sznajer Y, Craen M, Leventopoulos G, Mutesa L, Vandecasseye W, Massa G, Kayserili H, Sciort R, Fryns JP LET spectrum in children with N syndrome and S or R mutations. . Tumor Spectrum in Children With Noonan Syndrome and SOS1 or RAF1 Mutations. *Genes Chromosomes Cancer*. 2010;396(January):389–96.

86. Villani A, Greer MLC, Kalish JM, Nakagawara A, Nathanson KL, Pajtlar KW, et al. Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk. *Clinical Cancer Research*. 2017;23(12):e83–90.

Table 1. List of histologically confirmed malignant tumors reported in NS patients (the number is shown within parantheses when a mutation is reported in many patients).

Tumor	Gene	Germline variant at protein level	References
Juvenile myelomonocytic leukemia (n=40)	<i>PTPN11</i>	G60A D61G (2) D61H (2) D61N Y62D F71L A72G (3) T73I (11) E139D (3) F285L (2) N308D N308S G503A G503R (4) Q506P R65Q Y63C 179-181delGTG	(16) (4)(17) (25)(34)(38)(40)(47)(51)(58)
	<i>KRAS</i>	T58I	(20)
	<i>NRAS</i>	G13D G12S	(28) (43)
	<i>RIT1</i>	M90I	(56)
	<i>RAF</i>	S257L	(60)
Acute Lymphoblastic Leukemia (n=19)	<i>PTPN11</i>	N58S G60A Q79R E139D (2) Y279C N308D (5) G503R M504V (3) R501K ^a	(11) (14)(21) (35) (40)(54) (58)
	<i>SOS1</i>	M269R M269T	(12)
	<i>RIT1</i>	D81G	(36)
	<i>LZTR</i>	R210* ^a &c.2220-17C>A E563Q	(46)
Acute Myeloid Leukemia (n=1)	<i>PTPN11</i>	G268S	(61)
Non-Hodgkin's lymphoma (n=1)	<i>PTPN11</i>	P491L	(18)
Dysembryoplastic neuroepithelial tumor (n=6)	<i>PTPN11</i>	G60A D61G ^a E139D ^a N308D (2) N58K	(34) (40)(42) (44) (45)
Low grade glial tumor (n=1)	<i>RAF1</i>	G361A	(53)
High-grade glial tumor (n=2)	<i>PTPN11</i>	T2I N308D	(48)
Glioneuronal tumor (n=2)	<i>PTPN11</i>	N58D N308D	(29) (49)
Pilocytic astrocytoma (n=4)	<i>PTPN11</i>	G60A N308D ^a F491P	(30)(40)(45)
	<i>KRAS</i>	D153V	(40)
Pilomyxoid astrocytoma (n=1)	<i>PTPN11</i>	E139D	(41)
Oligo-astrocytoma (n=1)	<i>LZTR1</i>	R284C ^{a,b}	(50)
Oligodendroglioma (n=2)	<i>PTPN11</i>	E139N	(34)
	<i>PTPN11</i>	T22A	(22)
Hypothalamic glioma (n=1)	<i>PTPN11</i>	E139D	(19)
Medulloblastoma (n=1)	<i>PTPN11</i>	T468M	(37)

Neuroblastoma (n=4)	<i>PTPN11</i>	G60A I282M I282V N308D(2) D61G	(11)(23) (26) (34)(58)
Rhabdomyosarcoma (n=5)	<i>SOS1</i>	P102R ^a S548R L728I	(31) (32) (33)
	<i>RRAS2</i>	G23C G12R	(52). (55)
	<i>PTPN11</i>		(24)
Sertoli cell tumor (n=1)	<i>SOS1</i>	M269T ^a	(33)
Hepatoblastoma (n=1)	<i>PTPN11</i>	N308D	(27)
Giant cell tumour (n=1)	<i>RET</i>	A57G	(39)
Wilms Tumor (n=1)	<i>ERF</i>	I46N	(59)

^aTreated with growth hormone , ^b Cancer was diagnosed at 22 years old .

UNCORRECTED PROOF